Companies › Maze Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Genitourinary; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MZE782 | – | Phase 2 | Phenylketonuria (PKU) | Dec 2027 |
| MZE829 APOL1 kidney disease modulator | – | Phase 2 | Proteinuric Kidney Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06830629 | MZE829 | Phase 2 | Proteinuric Kidney Disease | Genitourinary | Sep 2026 |
| NCT07694440 | MZE782 | Phase 2 | Phenylketonuria (PKU) | Metabolic and endocrine | Dec 2027 |
Cash and short-term investments of $390m on 2026-09-30; operating cash outflow about $117m a year; runway about 40 months at that burn, to Jan 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Vifor Pharma Sparrow Pharmaceuticals Vogenx Neurocrine Switzerland SAb Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.